参考文献/References:
[1] Fokke C,Van Den Berg B,Drenthen JA,et al.Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria[J].Brain,2014,137(1):33-43.
[2] Cao-Lormeau VM,Blake A,Mons SA,et al.Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study[J].Lancet,2016,387(127):1531-1539.
[3] 卢祖能,王真真,关景霞.神经疾病临床症候学[M].北京:人民军医出版社,2015:391-405.
[4] Huizinga R,Van Den Berg B,Van Rijs WA,et al.Innate immunity to campylobacter jejuni in Guillain-Barre syndrome[J].Ann Neurol,2015,78(3):343-354.
[5] Yuki N,Susuki K,Koga M,et al.Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome[J].Proc Natl Acad Sci U S A,2004,101(31):11404-11409.
[6] Loshaj-Shala A,Regazzoni L,Daci A,et al.Guillain barré syndrome(GBS):new insights in the molecular mimicry between C.jejuni and human peripheral nerve(HPN)proteins[J].J Neuroimmunol,2015,289(12):168-176.
[7] Acoustics SI.Structural characterization of Camplobacter jejuni lipopolysaccharide outer cores associated with Guillain-Barre and Miller Fisher syndromes[J].Acoustics Speech&Signal Processing Newsletter IEEE,2007,15(3):1245-1254.
[8] Kountouras J,Deretzi G,Zavos C,et al.Helicobacter pylori infection May trigger Guillain-Barré syndrome,Fisher syndrome and Bickerstaff brainstem encephalitis[J].J Neurol Sci,2011,305(1/2):167-168.
[9] Boz C,Ozmenoglu M,Aktoz G,et al.Guillain-Barre syndrome during treatment with interferon alpha for hepatitis B[J].J Clin Neurosci,2004,11(5):523-525.
[10] Kobori S,Kubo T,Otani M,et al.Coexisting infectious diseases on admission as a risk factor for mechanical ventilation in patients with Guillain-Barre syndrome[J].Journal of Epidemiology,2017,27(7):311-316.
[11] Yuki N,Hartung HP.Guillain-Barre syndrome[J].N Engl J Med,2012,366(24):2294-2304.
[12] Styczynski AR,Malta J,Krowlucal ER,et al.Increased rates of Guillain-Barre syndrome associated with Zika virus outbreak in the Salvador metropolitan area,Brazil[J].PLOS Neglected Tropical Diseases,2017,11(8):e0005869.
[13] Tokars JI,Lewis P,Destefano F,et al.The risk of Guillain-Barre syndrome associated with influenza a(H1N1)2009 monovalent vaccine and 2009-2010 seasonal influenza vaccines: results from Self-Controlled analyses[J].Pharmacoepidemiol Drug Saf,2012,21(5):546-552.
[14] Martin AL,Sanz R,Sainz M,et al.Guillain-Barre syndrome and influenza vaccine:a meta-analysis[J].Vaccine,2015,33(31):3773-3778.
[15] Iqbal S,Li R,Gargiullo P,et al.Relationship between Guillain-Barr syndrome,influenza-related hospitalizations,and influenza vaccine coverage[J].Vaccine,2015,33(17):2045-2049.
[16] Grohskopf LA,Sokolow LZ,Broder KR,et al.Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2017-18 influenza season[J].MMWR Recomm Rep,2017,66(2):3-21.
[17] Gee J,Sukumaran L,Weintraub E.Risk of Guillain-Barr syndrome following quadrivalent human papillomavirus vaccine in the vaccine safety datalink[J].Vaccine,2017,35(43):5756-5758.
[18] Ben-Eliyahu S.The promotion of tumor metastasis by surgery and stress: Immunological basis and implications for psychoneuroimmunology[J].Brain Behav Immun,2003,17(1):S27-S36.
[19] Persson AK,Hoeijmakers JG,Estacion M,et al.Sodium channels,mitochondria,and axonal degeneration in peripheral neuropathy[J].Trends Mol Med,2016,22(5):377.
[20] Boghani Z,Livingston AD,Simpson EP,et al.Acute onset of Guillain-Barre syndrome after elective spinal surgery[J].World Neurosurg,2015,84(2):376-379.
[21] Bamberger PD,Thys DM.Guillain-Barr syndrome in a patient with pancreatic cancer after an Epidural-General anesthetic[J].Anesth Analg,2005,100(4):1197-1199.
[22] Sarmah B,Upadhyaya N.Familial Guillain-Barre syndrome: a case report with literature review[J].Neurol India,2017,65(4):804-807.
[23] Sang D,Chen Q,Liu X,et al.Fc receptor like 3 in Chinese patients of Han nationality with Guillain-Barré syndrome[J].J Neuroimmunol,2012,246(1/2):65.
[24] Myhr KM,Vagnes KS,Maroy TH,et al.Interleukin-10 promoter polymorphisms in patients with Guillain-Barre syndrome[J].J Neuroimmunol,2003,139(1/2):81-83.
[25] Patwala K,Crump N,De CP.Guillain-Barré syndrome in association with anti-tumour necrosis factor therapy:a case of mistaken identity[J].BMJ Case Rep,2017,doi:10.11361bcr-2017-219481.
[26] 贾建平,陈生弟.神经病学[M].北京:北京大学医学出版社,2004:350-353.
[27] Uncini A.Guillain-Barré syndrome:what have we learnt during one century a personal historical perspective[J].Rev Neurol,2016,172(10):632-644.
[28] Chang KH,Lyu RK,Ro YS,et al.Increased serum concentrations of transforming growth factor-β1(TGF-β1)in patients with Guillain-Barre syndrome[J].Clin Chim Acta,2016,461(6):8-13.
[29] Waksman BH,Adams RD.Allergic neuritis:an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants[J].J Exp Med,1955,102(2):213-236.
[30] Willison HJ,Jacobs BC,Van DP.A.Guillian-Barre syndrome[J].Lancet,2016,388(10045):717-727.
[31] Miyaji K,Devaux J,Yuki N,et al.Moesin is a possible target molecule for cytomegalovirus related Guillarin Barre syndrome[J].Neurology,2014,83(2):1186-1195.
[32] Uncini A,Kuwabara S.Nodopathies of the peripheral nerve: an emerging concept[J].J Neurol Neurosurg Psychiatry,2015,86(11):1186-1195.
[33] Mcgonigal R,Rowan EG,Greenshields KN,et al.Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice[J].Brain,2010,133(7):1944-1960.
[34] Zhang LJ,Guo HY,Zhang DQ,et al.Analysis of serum interleukin-27 and interleukin-35 concentrations in patients with Guillain-Barré syndrome[J].Clin Chim Acta,2017,468(5):5-9.
[35] Heikema AP,Jacobs BC,Horst-Kreft D,et al.Siglec-7 specifically recognizes Campylobacter jejuni strains associated with oculomotor weakness in Guillain-Barre syndrome and Miller Fisher syndrome[J].Clinical Microbiology and Infection,2013,19(2):E106-E112.
[36] Rodella U,Scorzeto M,Duregotti E,et al.An animal model of Miller Fisher syndrome: Mitochondrial Hydrogen peroxide is produced by the autoimmune attack of nerve terminals and activates Schwann cells[J].Neurobiol Dis,2016,96(12):95-104.
[37] Pietrini V,Pavesi G,Andreetta F.Miller fisher syndrome with positivity of anti-GAD antibodies[J].Clin Neurol Neurosurg,2013,115(8):1479-1481.
[38] Chan Y,Rathakrishnan R,Chan B.Impaired neuromuscular junction transmission in anti-GQ1b antibody negative Miller Fisher variant[J].Clin Neurol Neurosurg,2006,108(7):717-718.
[39] Alvin LT,Ravindra PV.Unique presentation of anti-GQ1b antibody syndrome[J].Can J Ophthalmol,2016,51(4):e119-e120.
[40] Van DB,Walgaard C,Drenthen J,et al.Guillain-Barre syndrome:pathogenesis,diagnosis,treatment and prognosis[J].Nat Rev Neurol,2014,10(8):469-482.
[41] Hughes RA,Brassington R,Gunn AA,et al.Corticosteroids for Guillain-Barré syndrome[J].Cochrane Database Syst Rev,2016,10(10):CD001446.
[42] Wang Y,Lv H,Shi QG,et al.Action mechanism of corticosteroids to aggravate guillain-barre syndrome[J].Journal of the Peripheral Nervous System,2015,20(2):245-246.
[43] Tzeng NS,Chang HA,Chung CH,et al.Risk of psychiatric disorders in Guillain-Barre syndrome:A nationwide,population-based,cohort study[J].J Neurol Sci,2017,381(10):88-94.